PIRS Pieris Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PIRS

Price (delayed)

$0.2039

Market cap

$20.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.35

Enterprise value

-$446,092

Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin ...

Highlights
The revenue has soared by 66% YoY and by 43% from the previous quarter
The company's gross profit has surged by 66% YoY and by 43% QoQ
The net income is up by 19% year-on-year but it has declined by 3.8% since the previous quarter
Pieris Pharmaceuticals's equity has decreased by 25% QoQ and by 15% YoY
Pieris Pharmaceuticals's quick ratio has decreased by 25% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pieris.com
Peers: AUPH GILD

Key stats

What are the main financial stats of PIRS
Market
Shares outstanding
98.85M
Market cap
$20.16M
Enterprise value
-$446,092
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
0.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.01
Earnings
Revenue
$47.36M
EBIT
-$28.06M
EBITDA
-$25.47M
Free cash flow
-$47.26M
Per share
EPS
-$0.35
Free cash flow per share
-$0.48
Book value per share
$0.31
Revenue per share
$0.48
TBVPS
$0.6
Balance sheet
Total assets
$59.38M
Total liabilities
$28.87M
Debt
$12.29M
Equity
$30.51M
Working capital
$30.22M
Liquidity
Debt to equity
0.4
Current ratio
2.05
Quick ratio
1.59
Net debt/EBITDA
0.81
Margins
EBITDA margin
-53.8%
Gross margin
100%
Net margin
-59.3%
Operating margin
-77.7%
Efficiency
Return on assets
-34.6%
Return on equity
-98.1%
Return on invested capital
-149.1%
Return on capital employed
-92%
Return on sales
-59.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PIRS stock price

How has the Pieris Pharmaceuticals stock price performed over time
Intraday
0%
1 week
-0.05%
1 month
-10.65%
1 year
-79.51%
YTD
-80.39%
QTD
-31.58%

Financial performance

How have Pieris Pharmaceuticals's revenue and profit performed over time
Revenue
$47.36M
Gross profit
$47.36M
Operating income
-$36.77M
Net income
-$28.06M
Gross margin
100%
Net margin
-59.3%
The revenue has soared by 66% YoY and by 43% from the previous quarter
The company's gross profit has surged by 66% YoY and by 43% QoQ
The net margin has soared by 51% YoY and by 27% QoQ
PIRS's operating margin is up by 48% year-on-year and by 31% since the previous quarter

Growth

What is Pieris Pharmaceuticals's growth rate over time

Valuation

What is Pieris Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.66
P/S
0.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.01
The EPS has grown by 26% YoY and by 5% from the previous quarter
PIRS's P/B is 85% below its 5-year quarterly average of 4.3 and 70% below its last 4 quarters average of 2.2
Pieris Pharmaceuticals's equity has decreased by 25% QoQ and by 15% YoY
The stock's P/S is 92% below its 5-year quarterly average of 5.1 and 80% below its last 4 quarters average of 2.1
The revenue has soared by 66% YoY and by 43% from the previous quarter

Efficiency

How efficient is Pieris Pharmaceuticals business performance
The ROS has soared by 51% YoY and by 27% from the previous quarter
PIRS's return on equity is down by 30% year-on-year and by 9% since the previous quarter
PIRS's return on invested capital is down by 30% since the previous quarter
Pieris Pharmaceuticals's ROA has decreased by 26% YoY and by 16% from the previous quarter

Dividends

What is PIRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PIRS.

Financial health

How did Pieris Pharmaceuticals financials performed over time
Pieris Pharmaceuticals's total assets is 106% more than its total liabilities
PIRS's total liabilities has dropped by 54% year-on-year and by 39% since the previous quarter
Pieris Pharmaceuticals's total assets has decreased by 40% YoY and by 32% from the previous quarter
The debt is 60% lower than the equity
PIRS's debt to equity is up by 38% from the previous quarter and by 25% YoY
Pieris Pharmaceuticals's equity has decreased by 25% QoQ and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.